Ipsen announced a voluntary withdrawal of tazemetostat (Tazverik) after an independent data monitoring committee identified cases of secondary hematologic malignancies in a confirmatory trial in follicular lymphoma. The company said it is discontinuing clinical studies of the drug and will stop market distribution while continuing to monitor treated patients. Tazverik, originally developed by Epizyme, had accelerated and later full approvals in limited indications. Ipsen and analysts characterized the commercial impact as limited, but the move raises broader questions about confirmatory-trial surveillance and post-approval safety management for oncology agents.